Oral chemotherapeutic agents in metastatic hormone-sensitive prostate cancer: A network meta-analysis of randomized controlled trials

BACKGROUND: Multiple oral chemotherapeutic agents for metastatic hormone-sensitive prostate cancer (mHSPC) have been developed for conjugated use with conventional androgen deprivation therapy (ADT). Several randomized controlled trials (RCTs) report significant benefits in mHSPC patients. Therefore...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yong Seong, Kim, Seong Hwan, Tae, Jong Hyun, Chang, In Ho, Kim, Tae-Hyoung, Myung, Soon Chul, Kim, Myoungsuk, Nguyen, Tuan Thanh, Choi, Joongwon, Kim, Jung Hoon, Kim, Jin Wook, Choi, Se Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513908/
https://www.ncbi.nlm.nih.gov/pubmed/37745904
http://dx.doi.org/10.1016/j.prnil.2023.06.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10513908/
https://www.ncbi.nlm.nih.gov/pubmed/37745904
http://dx.doi.org/10.1016/j.prnil.2023.06.003

Ejemplares similares